Synopsis
Synopsis
0
VMF
0
Weekly News Recap #Phispers
1. Bromide, Glycopyrronium
2. Glycopyrronium
3. Glycopyrronium Bromide
4. Nva 237
5. Nva-237
6. Nva237
7. Pyrrolidinium, 3-((cyclopentylhydroxyphenylacetyl)oxy)-1,1-dimethyl-, Bromide
1. 596-51-0
2. Glycopyrrolate Bromide
3. Robinul
4. Glycopyrronium Bromide
5. Gastrodyn
6. Nodapton
7. Tarodyl
8. Tarodyn
9. Asecryl
10. Cuvposa
11. Glycopyrronii Bromidum
12. Robanul
13. Ahr-504
14. Bromuro De Glicopirronio
15. Bromure De Glycopyrronium
16. Nva-237
17. Robinal
18. Seebri Neohaler
19. 3-hydroxy-1,1-dimethylpyrrolidinium Bromide Alpha-cyclopentylmandelate
20. Seebri
21. 1,1-dimethyl-3-hydroxypyrrolidinium Bromide Alpha-cyclopentylmandelate
22. 1-methyl-3-pyrrolidyl Alpha-phenylcyclopentaneglycolate Methobromide
23. 3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidin-1-ium Bromide
24. Pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethyl-,bromide
25. Ad-237
26. Pt-001
27. Nsc-250836
28. Nsc-251251
29. Nsc-251252
30. Copyrrolate
31. Dsstox_cid_3109
32. 3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidinium Bromide
33. (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate Bromide
34. Dsstox_rid_76878
35. Dsstox_gsid_23109
36. Glycopyrronium (bromide);glycopyrrolate (bromide)
37. Nva237
38. Robinul Forte
39. Pyrrolidinium,1-dimethyl-, Bromide
40. Seebri Breezhaler
41. 53808-86-9
42. (1,1-dimethylpyrrolidin-1-ium-3-yl) 2-cyclopentyl-2-hydroxy-2-phenylacetate;bromide
43. Smr000469282
44. Glycopyrrolate, Erythro-
45. Nsc 250836
46. Nsc 251251
47. Nsc 251252
48. Org-nc-45
49. Nsc250836
50. Nsc251251
51. Nsc251252
52. (2s,3's)-glycopyrrolate
53. Ahr 504
54. Glycopyrronium (as Bromide)
55. Nva 237
56. Glycopyrronii Bromidum [inn-latin]
57. Ncgc00179456-02
58. Wln: T5ktj A1 A1 Covxqr&- Al5tj &q &e
59. Einecs 209-887-0
60. Mfcd00072137
61. Bromure De Glycopyrronium [inn-french]
62. Bromuro De Glicopirronio [inn-spanish]
63. Chf5259
64. Glycopyrrolate [usan:usp]
65. Pt001
66. Chf-5259
67. Lonhala Magnair
68. Pyrrolidinium,1-dimethyl-, Bromide, .alpha.-cyclopentylmandelate
69. 1,1-dimethyl-3-hydroxypyrrolidinium Bromide .alpha.-cyclopentylmandelate
70. 1-methyl-3-pyrrolidinyl .alpha.-phenylcyclopentaneglycolate Methobromide
71. 3-hydroxy-1,1-dimethylpyrrolidinium Bromide-.alpha.-cyclopentylmandelate
72. Mandelic Acid, Ester With 3-hydroxy-1,1-dimethylpyrrolidinium Bromide
73. Cuvposa (tn)
74. Robinul (tn)
75. Glycopyrrolate (usp)
76. .beta.-1-methyl-3-pyrrolidyl-.alpha.-cyclopentylmandelate Methobromide
77. Seebri Breezhaler (tn)
78. Cas-596-51-0
79. Glycopyrrone Bromide
80. Schembl41436
81. Glycopyrronium Bromide ,(s)
82. Mls001424112
83. Mls002222301
84. 3-hydroxy-1,1-dimethylpyrrolidinium Bromide .alpha.-cyclopentylmandelate
85. Chembl1201027
86. Dtxsid6023109
87. Chebi:90972
88. Glycopyrrolate, >=98% (hplc)
89. Glycopyrronium Bromide (jan/inn)
90. Hms1570e14
91. Hms2051p12
92. Hms2094a05
93. Hms2097e14
94. Hms2235f12
95. Hms3259p04
96. Hms3369f10
97. Hms3393p12
98. Hms3714e14
99. Hms3885p14
100. Pharmakon1600-01505753
101. Amy22352
102. Bcp07110
103. Bcp33298
104. Chf-5992
105. Ex-a4155
106. Tox21_113144
107. Tox21_113145
108. Nsc759238
109. S4660
110. Akos015962136
111. Pyrrolidinium, 1,1-dimethyl-3-hydroxy-, Bromide, Alpha-cyclopentylmandelate
112. Pyrrolidinium, 3-hydroxy-1,1-dimethyl-, Bromide, Alpha-cyclopentylmandelate
113. Tox21_113144_1
114. Ccg-101030
115. Ccg-213543
116. Cs-1763
117. Nc00280
118. Nc00694
119. Nsc-759238
120. Ncgc00179456-04
121. Ac-23382
122. Hy-17465
123. Glycopyrrolate Erythro Isomer (ss-isomer)
124. Ft-0626787
125. G0392
126. D00540
127. A832400
128. Sr-01000763650
129. Sr-01000763650-3
130. Q27162963
131. Glycopyrrolate Erythro Isomer (mixture Of Rr-isomer And Ss-isomer)
132. Glycopyrrolate, United States Pharmacopeia (usp) Reference Standard
133. Glycopyrronium Bromide, European Pharmacopoeia (ep) Reference Standard
134. Glycopyrronium Impurity N, European Pharmacopoeia (ep) Reference Standard
135. 3-(2-cyclopentyl-2-hydroxy-2-phenylacetoxy)-1,1-dimethylpyrrolidin-1-iumbromide
136. 3-{[cyclopentyl(hydroxy)phenylacetyl]oxy}-1,1-dimethylpyrrolidin-1-ium Bromide
137. Glycopyrronium For Peak Identification, European Pharmacopoeia (ep) Reference Standard
Molecular Weight | 398.3 g/mol |
---|---|
Molecular Formula | C19H28BrNO3 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 4 |
Rotatable Bond Count | 5 |
Exact Mass | 397.12526 g/mol |
Monoisotopic Mass | 397.12526 g/mol |
Topological Polar Surface Area | 46.5 Ų |
Heavy Atom Count | 24 |
Formal Charge | 0 |
Complexity | 424 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 2 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 8 | |
---|---|
Drug Name | Cuvposa |
PubMed Health | Glycopyrrolate |
Drug Classes | Cholinergic Antagonist, Gastrointestinal Agent |
Drug Label | CUVPOSA is an anticholinergic drug available as an oral solution containing 1 mg glycopyrrolate per 5 mL. The chemical name for glycopyrrolate is pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl) oxy]-1,1-dimethyl-,bromide. The chemical structure is... |
Active Ingredient | Glycopyrrolate |
Dosage Form | Solution |
Route | Oral |
Strength | 1mg/5ml |
Market Status | Prescription |
Company | Merz Pharms |
2 of 8 | |
---|---|
Drug Name | Glycopyrrolate |
PubMed Health | Glycopyrrolate |
Drug Classes | Cholinergic Antagonist, Gastrointestinal Agent |
Drug Label | Glycopyrrolate tablets contain the synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name:3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. Its empirical fo... |
Active Ingredient | Glycopyrrolate |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | 1mg; 0.2mg/ml; 1.5mg; 2mg |
Market Status | Prescription |
Company | Stason Pharms; Vintage Pharms; Ranbaxy; Aurolife Pharma; Excellium; Hikma Farmaceutica; Par Pharm; Vintage; Luitpold; Dr Reddys Labs; Nexgen Pharma |
3 of 8 | |
---|---|
Drug Name | Robinul |
PubMed Health | Glycopyrrolate |
Drug Classes | Cholinergic Antagonist, Gastrointestinal Agent |
Drug Label | ROBINUL (glycopyrrolate) Injection is a synthetic anticholinergic agent. Each 1 mL contains:Glycopyrrolate, USP 0.2 mgWater for Injection, USP q.s.Benzyl Alcohol, NF 0.9% (preservative)pH adjusted, when necessary, with hydrochloric acid and/or sodium... |
Active Ingredient | Glycopyrrolate |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | 1mg; 0.2mg/ml |
Market Status | Prescription |
Company | Shionogi; Hikma Maple |
4 of 8 | |
---|---|
Drug Name | Robinul forte |
PubMed Health | Glycopyrrolate (By mouth) |
Drug Classes | Cholinergic Antagonist, Gastrointestinal Agent |
Drug Label | Robinul and Robinul Forte tablets contain the synthetic anticholinergic, glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1, 1-dimethylpyrrolidinium bromide... |
Active Ingredient | Glycopyrrolate |
Dosage Form | Tablet |
Route | Oral |
Strength | 2mg |
Market Status | Prescription |
Company | Shionogi |
5 of 8 | |
---|---|
Drug Name | Cuvposa |
PubMed Health | Glycopyrrolate |
Drug Classes | Cholinergic Antagonist, Gastrointestinal Agent |
Drug Label | CUVPOSA is an anticholinergic drug available as an oral solution containing 1 mg glycopyrrolate per 5 mL. The chemical name for glycopyrrolate is pyrrolidinium, 3-[(cyclopentylhydroxyphenylacetyl) oxy]-1,1-dimethyl-,bromide. The chemical structure is... |
Active Ingredient | Glycopyrrolate |
Dosage Form | Solution |
Route | Oral |
Strength | 1mg/5ml |
Market Status | Prescription |
Company | Merz Pharms |
6 of 8 | |
---|---|
Drug Name | Glycopyrrolate |
PubMed Health | Glycopyrrolate |
Drug Classes | Cholinergic Antagonist, Gastrointestinal Agent |
Drug Label | Glycopyrrolate tablets contain the synthetic anticholinergic glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name:3-[(cyclopentylhydroxyphenylacetyl)oxy]-1,1-dimethylpyrrolidinium bromide. Its empirical fo... |
Active Ingredient | Glycopyrrolate |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | 1mg; 0.2mg/ml; 1.5mg; 2mg |
Market Status | Prescription |
Company | Stason Pharms; Vintage Pharms; Ranbaxy; Aurolife Pharma; Excellium; Hikma Farmaceutica; Par Pharm; Vintage; Luitpold; Dr Reddys Labs; Nexgen Pharma |
7 of 8 | |
---|---|
Drug Name | Robinul |
PubMed Health | Glycopyrrolate |
Drug Classes | Cholinergic Antagonist, Gastrointestinal Agent |
Drug Label | ROBINUL (glycopyrrolate) Injection is a synthetic anticholinergic agent. Each 1 mL contains:Glycopyrrolate, USP 0.2 mgWater for Injection, USP q.s.Benzyl Alcohol, NF 0.9% (preservative)pH adjusted, when necessary, with hydrochloric acid and/or sodium... |
Active Ingredient | Glycopyrrolate |
Dosage Form | Tablet; Injectable |
Route | Injection; Oral |
Strength | 1mg; 0.2mg/ml |
Market Status | Prescription |
Company | Shionogi; Hikma Maple |
8 of 8 | |
---|---|
Drug Name | Robinul forte |
PubMed Health | Glycopyrrolate (By mouth) |
Drug Classes | Cholinergic Antagonist, Gastrointestinal Agent |
Drug Label | Robinul and Robinul Forte tablets contain the synthetic anticholinergic, glycopyrrolate. Glycopyrrolate is a quaternary ammonium compound with the following chemical name: 3-[(cyclopentylhydroxyphenylacetyl)oxy]-1, 1-dimethylpyrrolidinium bromide... |
Active Ingredient | Glycopyrrolate |
Dosage Form | Tablet |
Route | Oral |
Strength | 2mg |
Market Status | Prescription |
Company | Shionogi |
Tovanor Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Seebri Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Enurev Breezhaler is indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
Symptomatic treatment of severe sialorrhoea (chronic pathological drooling) in children and adolescents aged 3 years and older with chronic neurological disorders.
Treatment of sialorrhoea
Chronic obstructive pulmonary disease
Treatment of sialorrhoea
Treatment of hyperhidrosis
Muscarinic Antagonists
Drugs that bind to but do not activate MUSCARINIC RECEPTORS, thereby blocking the actions of endogenous ACETYLCHOLINE or exogenous agonists. Muscarinic antagonists have widespread effects including actions on the iris and ciliary muscle of the eye, the heart and blood vessels, secretions of the respiratory tract, GI system, and salivary glands, GI motility, urinary bladder tone, and the central nervous system. (See all compounds classified as Muscarinic Antagonists.)
Adjuvants, Anesthesia
Agents that are administered in association with anesthetics to increase effectiveness, improve delivery, or decrease required dosage. (See all compounds classified as Adjuvants, Anesthesia.)
R03BB06
R03BB06
R03BB06
A03AB02
A03AB02
S76 | LUXPHARMA | Pharmaceuticals Marketed in Luxembourg | Pharmaceuticals marketed in Luxembourg, as published by d'Gesondheetskeess (CNS, la caisse nationale de sante, www.cns.lu), mapped by name to structures using CompTox by R. Singh et al. (in prep.). List downloaded from https://cns.public.lu/en/legislations/textes-coordonnes/liste-med-comm.html. Dataset DOI:10.5281/zenodo.4587355
A - Alimentary tract and metabolism
A03 - Drugs for functional gastrointestinal disorders
A03A - Drugs for functional gastrointestinal disorders
A03AB - Synthetic anticholinergics, quaternary ammonium compounds
A03AB02 - Glycopyrronium bromide
R - Respiratory system
R03 - Drugs for obstructive airway diseases
R03B - Other drugs for obstructive airway diseases, inhalants
R03BB - Anticholinergics
R03BB06 - Glycopyrronium bromide
GDUFA
DMF Review : Complete
Rev. Date : 2018-02-16
Pay. Date : 2017-07-06
DMF Number : 31836
Submission : 2017-07-22
Status : Active
Type : II
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
GDUFA
DMF Review : Complete
Rev. Date : 2013-10-05
Pay. Date : 2013-09-30
DMF Number : 18106
Submission : 2005-02-22
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 19026
Submission : 2005-12-10
Status : Active
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2015-03-13
Pay. Date : 2015-03-06
DMF Number : 16972
Submission : 2003-11-13
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 6044
Submission : 1985-10-01
Status : Inactive
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 16967
Submission : 2003-11-17
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 20578
Submission : 2007-05-31
Status : Inactive
Type : II
GDUFA
DMF Review : Complete
Rev. Date : 2012-11-23
Pay. Date : 2012-12-06
DMF Number : 19710
Submission : 2006-08-28
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 18727
Submission : 2005-08-31
Status : Active
Type : II
GDUFA
DMF Review : N/A
Rev. Date :
Pay. Date :
DMF Number : 430
Submission : 1961-04-18
Status : Inactive
Type : II
Glycopyrronium Bromide, Micronised, Non-micronis...
Certificate Number : R1-CEP 2017-182 - Rev 00
Status : Valid
Issue Date : 2023-08-17
Type : Chemical
Substance Number : 1783
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
Certificate Number : R1-CEP 2012-129 - Rev 01
Status : Valid
Issue Date : 2020-07-30
Type : Chemical
Substance Number : 1783
Certificate Number : R1-CEP 2014-194 - Rev 01
Status : Valid
Issue Date : 2021-02-18
Type : Chemical
Substance Number : 1783
Certificate Number : R0-CEP 2021-154 - Rev 00
Status : Valid
Issue Date : 2022-11-16
Type : Chemical
Substance Number : 1783
Certificate Number : R1-CEP 2012-017 - Rev 01
Status : Valid
Issue Date : 2020-12-01
Type : Chemical
Substance Number : 1783
Glycopyrronium Bromide, Micronised, Non-micronis...
Certificate Number : R0-CEP 2021-222 - Rev 01
Status : Valid
Issue Date : 2023-01-16
Type : Chemical
Substance Number : 1783
Certificate Number : R1-CEP 2013-110 - Rev 04
Status : Valid
Issue Date : 2023-08-23
Type : Chemical
Substance Number : 1783
Certificate Number : R0-CEP 2020-077 - Rev 00
Status : Valid
Issue Date : 2021-09-14
Type : Chemical
Substance Number : 1783
Certificate Number : R0-CEP 2021-268 - Rev 00
Status : Valid
Issue Date : 2023-01-11
Type : Chemical
Substance Number : 1783
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
Glycopyrronium bromide "For manufacturing purposes only"
Registration Number : 230MF10066
Registrant's Address : 21,chemin de la Sauvegarde 21 Ecully Parc - CS 33167 69134 Ecully Cedex France
Initial Date of Registration : 2018-05-21
Latest Date of Registration : 2019-05-07
Registration Number : 304MF10139
Registrant's Address : Strada Rivoltana Km 6/7 20053 Rodano Milano Italy
Initial Date of Registration : 2022-10-05
Latest Date of Registration : 2022-10-05
Registrant Name : Samoh Pharmaceutical Co., Ltd.
Registration Date : 2020-11-03
Registration Number : 20201103-211-J-782
Manufacturer Name : INKE SA
Manufacturer Address : C/Argent 1, Area Industrial del Llobregat 08755 Castellbisbal Barcelona, Spain
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
Registrant Name : BC World Healthcare Co., Ltd.
Registration Date : 2024-10-07
Registration Number : 20241007-211-J-1701
Manufacturer Name : PCAS Finland Oy
Manufacturer Address : Messukentankatu 8 FI-20210 Turku, Finland
Registrant Name : AstraZeneca Korea Ltd.
Registration Date : 2021-07-05
Registration Number : 20210705-211-J-1053
Manufacturer Name : PCAS Finland Oy@AstraZeneca ...
Manufacturer Address : Messukentankatu 8, 20210 Turku, Finland@Forskargatan 18, Sodertalje, 151 36, Sweden
Registrant Name : AstraZeneca Korea Ltd.
Registration Date : 2022-09-08
Registration Number : 20220908-211-J-1360
Manufacturer Name : PCAS Finland Oy@AstraZeneca ...
Manufacturer Address : Messukentankatu 8, 20210 Turku, Finland@200 Cardinal Way Redwood City, CA 94063 USA
Glycopyrronium bromide (micronized)
Registrant Name : Aging Life Science Co., Ltd.
Registration Date : 2022-01-12
Registration Number : 20220112-211-J-1206
Manufacturer Name : Harman Finochem Limited
Manufacturer Address : Plot No. E-7, E-8 & E-9, MIDC , Chikalthana, Aurangabad-431006, Maharashtra State, In...
Registrant Name : Masung LS Co., Ltd.
Registration Date : 2020-06-03
Registration Number : 20200603-210-J-438
Manufacturer Name : Suven Pharmaceuticals Limite...
Manufacturer Address : Plot Nos. 262 to 271, IDA, Pashamylaram(V), Patancheru(M), Sangareddy District Telang...
About the Company : Inke S.A., is focused since 1980 in the development and manufacture of the highest quality Active Pharmaceutical Ingredients (APIs) with complex synthesis processes for diverse the...
Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients & provides custom-made solutions.
About the Company : Since its inception in 2003, Seqens has grown to become a global leader in pharmaceutical solutions and specialty ingredients. Seqens supports its customers in developing, scaling ...
LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.
About the Company : LGM Pharma is a global leader in sourcing hard-to-find APIs and intermediates for the pharmaceutical and biotech industries. LGM is also a full service CDMO providing formulation, ...
About the Company : Jai Radhe Sales was founded in 1999 as an out-of-the-box distribution firm specializing in the global supply of high-quality pharmaceutical ingredients. The firm provides complete ...
Vamsi Labs is one of the major manufacturers of Anti-asthmatic, Anti-migraine & Anti-psychotic APIs.
About the Company : Vamsi Labs, established in 1991, is a leading Indian API manufacturer. Specializing in anti-asthmatic, anti-migraine & anti-psychotic APIs, it caters to domestic & international ma...
About the Company : Balaji corporation was established in 2006, the group have two branch in india.To play a key role as innovative and delenadable service provided.The company was quick to envisage t...
About the Company : Specialising in general and oncology APIs, Bo-Chem is a state-of-the-art, manufacturing facility with an emphasis on unparalleled quality, devoted services, punctuality, fair price...
About the Company : Guangzhou Tosun Pharmaceutical was founded in 1999, which mainly focuses on importation & exportation of Active Pharmaceutical Ingrediants, Chemical Raw Materials, Intermediate, Ex...
About the Company : Founded more than 40 years ago, our purpose has always been to provide high-quality, affordable medicines to the people who need them. Based on the solid foundation we have built, ...
About the Company : We are a renowned pharma player having a wide range of quality products and specialise in manufacturing Active Pharmaceutical Ingredients (API) and Drug Intermediates (DI’s). The...
API Imports and Exports
Importing Country | Total Quantity (KGS) |
Average Price (USD/KGS) |
Number of Transactions |
---|
Upgrade, download data, analyse, strategize, subscribe with us
Details:
QVM149 combines the bronchodilation of indacaterol acetate (a LABA) and the antimuscarinic effects of glycopyrronium bromide (a LAMA) with mometasone furoate in a precise once-daily formulation, delivered via the dose-confirming Breezhaler® device.
Lead Product(s): Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Enerzair Breezhaler
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Novartis Pharmaceuticals Corporation
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 07, 2020
Lead Product(s) : Indacaterol Acetate,Glycopyrronium Bromide,Mometasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Novartis Pharmaceuticals Corporation
Deal Size : Not Applicable
Deal Type : Not Applicable
QVM149 Receives Regulatory Approval in Europe and Japan
Details : QVM149 combines the bronchodilation of indacaterol acetate (a LABA) and the antimuscarinic effects of glycopyrronium bromide (a LAMA) with mometasone furoate in a precise once-daily formulation, delivered via the dose-confirming Breezhaler® device.
Brand Name : Enerzair Breezhaler
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 07, 2020
Details:
Cuvposa is an anticholinergic indicated to reduce chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Neurology Brand Name: Cuvposa-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 20, 2024
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Granules India Gets USFDA Nod for Generic Glycopyrrolate Oral Solution
Details : Cuvposa is an anticholinergic indicated to reduce chronic severe drooling in patients aged 3-16 years with neurologic conditions associated with problem drooling.
Brand Name : Cuvposa-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 20, 2024
Details:
Breztri Aerosphere is a combination of budesonide, glycopyrrolate and formoterol fumarate indicated for the maintenance treatment of patients with COPD.
Lead Product(s): Budesonide,Glycopyrronium Bromide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Breztri Aerosphere
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2024
Lead Product(s) : Budesonide,Glycopyrronium Bromide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
AstraZeneca Pharma Pharma India to launch Breztri Aerosphere in Jan 2025
Details : Breztri Aerosphere is a combination of budesonide, glycopyrrolate and formoterol fumarate indicated for the maintenance treatment of patients with COPD.
Brand Name : Breztri Aerosphere
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2024
Details:
Vilfuro-G (vilanterol, fluticasone furoate & glycopyrronium bromide) is world's first fixed-dose triple combination drug which is approved for the treatment of chronic obstructive pulmonary disease (COPD).
Lead Product(s): Vilanterol Trifenatate,Fluticasone Furoate,Glycopyrronium Bromide
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Vilfuro-G
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 23, 2023
Lead Product(s) : Vilanterol Trifenatate,Fluticasone Furoate,Glycopyrronium Bromide
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Launches World’s First Fixed-dose Triple Combination Drug, Vilfuro-G® for COPD Management...
Details : Vilfuro-G (vilanterol, fluticasone furoate & glycopyrronium bromide) is world's first fixed-dose triple combination drug which is approved for the treatment of chronic obstructive pulmonary disease (COPD).
Brand Name : Vilfuro-G
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 23, 2023
Details:
A fixed dose combination of vilanterol (adrenergic receptor beta-2 agonist), glycopyrrolate & fluticasone furoate is approved for the treatment of chronic obstructive pulmonary disease.
Lead Product(s): Vilanterol Trifenatate,Glycopyrronium Bromide,Fluticasone Furoate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Undisclosed
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 13, 2023
Lead Product(s) : Vilanterol Trifenatate,Glycopyrronium Bromide,Fluticasone Furoate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : A fixed dose combination of vilanterol (adrenergic receptor beta-2 agonist), glycopyrrolate & fluticasone furoate is approved for the treatment of chronic obstructive pulmonary disease.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
October 13, 2023
Details:
PREVDUO (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S for Neuromuscular blockade.
Lead Product(s): Neostigmine Methylsulfate,Glycopyrronium Bromide
Therapeutic Area: Neurology Brand Name: Prevduo
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2023
Lead Product(s) : Neostigmine Methylsulfate,Glycopyrronium Bromide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : PREVDUO (neostigmine methylsulfate and glycopyrrolate injection) pre-filled syringe, the first and only FDA-approved neostigmine–glycopyrrolate combination product in the U.S for Neuromuscular blockade.
Brand Name : Prevduo
Molecule Type : Small molecule
Upfront Cash : Not Applicable
June 12, 2023
Details:
Glycopyrrolate is an anticholinergic agents, competitively inhibit binding of the neurotransmitter, acetylcholine. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Gastroenterology Brand Name: Glycopyrrolate-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 09, 2023
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Gastroenterology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lupin Receives Approval From USFDA For Glycopyrrolate Injection USP
Details : Glycopyrrolate is an anticholinergic agents, competitively inhibit binding of the neurotransmitter, acetylcholine. Thus, it diminishes the volume and free acidity of gastric secretions and controls excessive pharyngeal, tracheal, and bronchial secretions...
Brand Name : Glycopyrrolate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 09, 2023
Details:
Glycopyrrolate injection is used as a pre-operative medication to inhibit salivary gland and respiratory secretions also as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not tolerated.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Neurology Brand Name: Glycopyrrolate-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 01, 2022
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Alembic Pharma Gets USFDA Nod For Generic Version Of Glycopyrrolate Injection
Details : Glycopyrrolate injection is used as a pre-operative medication to inhibit salivary gland and respiratory secretions also as adjunctive therapy for the treatment of peptic ulcer when rapid anticholinergic effect is desired or when oral medication is not t...
Brand Name : Glycopyrrolate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
November 01, 2022
Details:
Glycopyrrolate Injection, USP 0.6 mg per 3 mL Simplist prefilled syringe may be administered prior to or concomitantly with Simplist Neostigmine Methylsulfate Injection, USP 3 mg per 3 mL prefilled syringe for reversal of neuromuscular blockade.
Lead Product(s): Glycopyrronium Bromide
Therapeutic Area: Neurology Brand Name: Glycopyrrolate-Generic
Study Phase: ApprovedProduct Type: Small molecule
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 25, 2022
Lead Product(s) : Glycopyrronium Bromide
Therapeutic Area : Neurology
Highest Development Status : Approved
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Fresenius Kabi Expands Ready-to-Administer Portfolio with Glycopyrrolate Injection, USP Simplist®...
Details : Glycopyrrolate Injection, USP 0.6 mg per 3 mL Simplist prefilled syringe may be administered prior to or concomitantly with Simplist Neostigmine Methylsulfate Injection, USP 3 mg per 3 mL prefilled syringe for reversal of neuromuscular blockade.
Brand Name : Glycopyrrolate-Generic
Molecule Type : Small molecule
Upfront Cash : Not Applicable
July 25, 2022
Details:
A recently completed Phase I clinical trial of the propellant HFO-1234ze in a pMDI containing budesonide, glycopyrronium, formoterol fumarate in healthy adults was positive, demonstrating similar safety and tolerability profile.
Lead Product(s): Budesonide,Glycopyrronium Bromide,Formoterol Fumarate
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Breztri Aerosphere
Study Phase: Phase IProduct Type: Small molecule
Sponsor: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 22, 2022
Lead Product(s) : Budesonide,Glycopyrronium Bromide,Formoterol Fumarate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : AstraZeneca
Deal Size : Undisclosed
Deal Type : Partnership
Details : A recently completed Phase I clinical trial of the propellant HFO-1234ze in a pMDI containing budesonide, glycopyrronium, formoterol fumarate in healthy adults was positive, demonstrating similar safety and tolerability profile.
Brand Name : Breztri Aerosphere
Molecule Type : Small molecule
Upfront Cash : Undisclosed
February 22, 2022
DRUG PRODUCT COMPOSITIONS
Related Excipient Companies
Excipients by Applications
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
A Glycopyrronium manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Glycopyrronium, including repackagers and relabelers. The FDA regulates Glycopyrronium manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Glycopyrronium API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Glycopyrronium manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Glycopyrronium supplier is an individual or a company that provides Glycopyrronium active pharmaceutical ingredient (API) or Glycopyrronium finished formulations upon request. The Glycopyrronium suppliers may include Glycopyrronium API manufacturers, exporters, distributors and traders.
click here to find a list of Glycopyrronium suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
A Glycopyrronium DMF (Drug Master File) is a document detailing the whole manufacturing process of Glycopyrronium active pharmaceutical ingredient (API) in detail. Different forms of Glycopyrronium DMFs exist exist since differing nations have different regulations, such as Glycopyrronium USDMF, ASMF (EDMF), JDMF, CDMF, etc.
A Glycopyrronium DMF submitted to regulatory agencies in the US is known as a USDMF. Glycopyrronium USDMF includes data on Glycopyrronium's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Glycopyrronium USDMF is kept confidential to protect the manufacturer’s intellectual property.
click here to find a list of Glycopyrronium suppliers with USDMF on PharmaCompass.
The Pharmaceuticals and Medical Devices Agency (PMDA) established the Japan Drug Master File (JDMF), also known as the Master File (MF), to permit Japanese and foreign manufacturers of drug substances, intermediates, excipients, raw materials, and packaging materials (‘Products’) to voluntarily register confidential information about the production and management of their products in Japan.
The Glycopyrronium Drug Master File in Japan (Glycopyrronium JDMF) empowers Glycopyrronium API manufacturers to present comprehensive information (e.g., production methods, data, etc.) to the review authority, i.e., PMDA (Pharmaceuticals & Medical Devices Agency).
PMDA reviews the Glycopyrronium JDMF during the approval evaluation for pharmaceutical products. At the time of Glycopyrronium JDMF registration, PMDA checks if the format is accurate, if the necessary items have been included (application), and if data has been attached.
click here to find a list of Glycopyrronium suppliers with JDMF on PharmaCompass.
In Korea, the Ministry of Food and Drug Safety (MFDS) is in charge of regulating pharmaceutical products and services.
Pharmaceutical companies submit a Glycopyrronium Drug Master File in Korea (Glycopyrronium KDMF) to the MFDS, which includes comprehensive information about the production, processing, facilities, materials, packaging, and testing of Glycopyrronium. The MFDS reviews the Glycopyrronium KDMF as part of the drug registration process and uses the information provided in the Glycopyrronium KDMF to evaluate the safety and efficacy of the drug.
After submitting a Glycopyrronium KDMF to the MFDS, the registered manufacturer can provide importers or distributors with the registration number without revealing confidential information to Korean business partners. Applicants seeking to register their Glycopyrronium API can apply through the Korea Drug Master File (KDMF).
click here to find a list of Glycopyrronium suppliers with KDMF on PharmaCompass.
A Glycopyrronium CEP of the European Pharmacopoeia monograph is often referred to as a Glycopyrronium Certificate of Suitability (COS). The purpose of a Glycopyrronium CEP is to show that the European Pharmacopoeia monograph adequately controls the purity of Glycopyrronium EP produced by a given manufacturer. Suppliers of raw materials can prove the suitability of Glycopyrronium to their clients by showing that a Glycopyrronium CEP has been issued for it. The manufacturer submits a Glycopyrronium CEP (COS) as part of the market authorization procedure, and it takes on the role of a Glycopyrronium CEP holder for the record. Additionally, the data presented in the Glycopyrronium CEP (COS) is managed confidentially and offers a centralized system acknowledged by numerous nations, exactly like the Glycopyrronium DMF.
A Glycopyrronium CEP (COS) is recognised by all 36 nations that make up the European Pharmacopoeia Convention. Glycopyrronium CEPs may be accepted in nations that are not members of the Ph. Eur. at the discretion of the authorities there.
click here to find a list of Glycopyrronium suppliers with CEP (COS) on PharmaCompass.
A Glycopyrronium written confirmation (Glycopyrronium WC) is an official document issued by a regulatory agency to a Glycopyrronium manufacturer, verifying that the manufacturing facility of a Glycopyrronium active pharmaceutical ingredient (API) adheres to the Good Manufacturing Practices (GMP) regulations of the importing country. When exporting Glycopyrronium APIs or Glycopyrronium finished pharmaceutical products to another nation, regulatory agencies frequently require a Glycopyrronium WC (written confirmation) as part of the regulatory process.
click here to find a list of Glycopyrronium suppliers with Written Confirmation (WC) on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Glycopyrronium as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Glycopyrronium API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Glycopyrronium as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Glycopyrronium and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Glycopyrronium NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Glycopyrronium suppliers with NDC on PharmaCompass.
Glycopyrronium Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Glycopyrronium GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Glycopyrronium GMP manufacturer or Glycopyrronium GMP API supplier for your needs.
A Glycopyrronium CoA (Certificate of Analysis) is a formal document that attests to Glycopyrronium's compliance with Glycopyrronium specifications and serves as a tool for batch-level quality control.
Glycopyrronium CoA mostly includes findings from lab analyses of a specific batch. For each Glycopyrronium CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Glycopyrronium may be tested according to a variety of international standards, such as European Pharmacopoeia (Glycopyrronium EP), Glycopyrronium JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Glycopyrronium USP).
LOOKING FOR A SUPPLIER?